The 2024 Asia Scam Report surveyed nearly 25,000 participants across 13 Asia markets
Upcoming Global Anti-Scam Summit – Asia is taken place in Singapore Oct 21-22
SINGAPORE , Oct. 16, 2024 /PRNewswire/ -- As scams continue to escalate across Asia, the Global Anti-Scam Alliance (GASA) and ScamAdviser jointly announce the release of the Asia Scam Report before the Global Anti-Scam Summit – Asia in Singapore on October 21-22. This comprehensive report provides critical insights into the evolving landscape of digital scams across the region, offering actionable data for governments, businesses, and individuals.
"As scammers become more sophisticated, leveraging AI to scale their attacks, our defense strategies must advance rapidly." said Jorij Abraham, Managing Director of GASA. "The Asia Scam Report sheds light on the alarming rise of scams across the region. We are honored to collaborate with industry partners to strengthen our collective efforts in protecting citizens and businesses throughout Asia."
The 2024 Asia Scam Report, conducted by the Global Anti-Scam Alliance (GASA) and ScamAdviser surveyed nearly 25,000 participants across 13 areas including China, Hong Kong, India, Indonesia, Japan, Malaysian, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam. The findings provide an in-depth look at scam threats, the methods employed by scammers, and the responses from citizens across the region.
The Asia Scam Report reveals key findings, including:
- Scam-related losses are estimated to reach US$688.42 billion across 13 Asian markets, underscoring the urgent need for stronger scam prevention strategies.
- The most prominent channels used for scams in Asia are, in order: Text/SMS, Phone calls, Chat Apps, Social Media, and Email.
- Nearly half of Asians believe online platforms should be held accountable for their losses, while Singaporeans tend to place the most blame on banks and payment providers.
- 1 in 4 scams are completed in just minutes, and only 8% of scam cases span over a year, reflecting the efficiency and speed of these operations.
- Identity theft is the most common scam in China, Japan, Singapore, Taiwan, Thailand, and Vietnam. In Malaysia, Indonesia, and Pakistan, investment scams dominate, while shopping scams are most prevalent in India and the Philippines.
- In most markets, expectation is that online platforms and website providers should be responsible for refund the loss of scams.
Join the Global Anti-Scam Asia Summit – Asia
The findings of the Asia Scam Report will be further discussed at the upcoming Global Anti-Scam Summit ï¼Asia, where experts from across the globe will share their insights on combating the growing scam. Besides ScamAdviser, attendees will have the opportunity to engage with thought leaders, including representatives from Amazon, Mastercard, Gogolook, Google, and Meta, as well as officials from law enforcement, financial authorities, and non-profit organizations.
For more information on Global Anti-Scam Summit – Asia, please visit the official website: https://www.gasa.org/gass-2024-asia
To download the 2024 Asia Scam Report, please visit: https://www.gasa.org/research
About GASA
The Global Anti Scam Alliance's (GASA) mission is to protect consumers worldwide from scams by raising awareness, enabling hands-on tools, facilitating knowledge sharing, organizing research, and offering training and education.
For more information, please refer to: https://www.gasa.org/
About ScamAdviser
ScamAdviser, a leading brand in global enterprise scam prevention solutions, based in Amsterdam, Netherlands. Leveraging AI and a comprehensive database network, ScamAdviser has developed its own website risk rating technology. Its Anti-Scam Intelligence is built on the world's most comprehensive digital anti-scam database.
ScamAdviser excels in implementing customized anti-scam technologies into corporate operations, helping clients protect consumers and stay ahead of global compliance trends. As a founding member of the Global Anti-Scam Alliance, ScamAdviser's partners and clients span Europe, the Americas, and Asia, covering both public and private sectors. With the world's largest scam database, we share insights with 400+ partners, collectively protecting more than 1 billion consumers worldwide.
For more information, please refer to: https://www.scamadviser.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
GASA and ScamAdviser Reveal Potential $688 billion loss to scams in Asia
Late-breaking HRX data advance Field Medical's "instantaneous ablation" workflow and expand the clinical evidence for high-voltage focal PFA with the FieldForce™ PFA System
ATLANTA and CARLSBAD, Calif., Sept. 20, 2026 /PRNewswire/ -- Field Medical, Inc., advancing high-voltage focal pulsed field ablation (PFA) for complex arrhythmias, today announced publication of 12-month results from the first-in-human Field PULSE trial in JACC: Clinical Electrophysiology. The findings were presented simultaneously as a Late-Breaking Clinical Trial at HRX Live 2026.
Field Medical developed the FieldForce™ PFA System around a high-voltage focal PFA architecture designed first for the ventricle, where depth, stability and control are among the most difficult challenges in ablation. Field PULSE extends that work into the atrium and evaluates a subsecond point-by-point workflow Field Medical terms "instantaneous ablation." In this study, the approach was associated with procedural efficiency, durable pulmonary vein isolation (PVI) and flexibility beyond the pulmonary veins, without the need for prolonged catheter stability.
Key Findings:
- Procedural efficiency with subsecond focal PFA: 13-minute median elapsed PVI ablation time, with a fastest time of 7.7 minutes
- Durable PVI with the optimized waveform: 94.2% per-vein durability reflecting progressive improvement with waveform evolution
- Flexible focal ablation: 49% of patients received non-PV ablation for additional atrial targets
- No primary safety events were observed
- 80% freedom from atrial arrhythmias at 12 months with the optimized waveform
"Field PULSE demonstrates the feasibility of truly instantaneous focal PFA," said Vivek Reddy, M.D., co-principal investigator, lead author and electrophysiologist at Mount Sinai Health System. "Delivering the full application in less than 200 milliseconds reduces the need for prolonged catheter stability while preserving the flexibility of point-by-point ablation. The procedural efficiency, safety and pulmonary vein durability observed with the optimized waveform support continued clinical development of this approach."
The publication builds on Field Medical's peer-reviewed clinical work in ventricular tachycardia. Six-month outcomes from the company's first-in-human VCAS trial were published in Circulation in 2025. Field PULSE now adds first-in-human, peer-reviewed atrial data evaluating the same high-voltage focal PFA architecture through a distinct focal workflow in a different cardiac substrate.
"We designed FieldForce to solve some of the hardest problems in focal cardiac ablation, beginning in the ventricle," said Mark A. Turco, M.D., president and chief executive officer of Field Medical. "Field PULSE demonstrates that the same high-voltage focal PFA architecture can support an 'instantaneous ablation' workflow in the atrium. This growing body of evidence reinforces the range of the platform: depth and focal control in the ventricle, speed and precision in the atrium, and the versatility to address very different cardiac substrates through a familiar point-by-point approach. These results add important clinical evidence as we continue to advance our differentiated PFA platform."
The study, "High-Voltage Focal PFA Catheter for 'Instant' Point-By-Point Ablation: The First-In-Human FIELD-PULSE Trial to Treat AF," was published online in JACC: Clinical Electrophysiology concurrent with the HRX presentation. DOI: 10.1016/j.jacep.2026.09.001.
About Field Medical®, Inc.
Field Medical is a clinical-stage medical technology company committed to advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. The company was founded by Steven Mickelsen, M.D., CTO, a pioneer and global thought leader in PFA whose work has helped shape the evolution of the field. The FieldForce PFA System integrates a focal catheter design with proprietary FieldBending™ energy designed to safely deliver efficient, precise ablation with the goal of improving outcomes in ventricular and atrial arrhythmia treatment. In 2024, Field Medical earned Breakthrough Device Designation and gained entry into the FDA TAP Pilot Program for its ventricular tachycardia indication. In October 2025, the VCAS trial was published in Circulation.
For more information, visit fieldmedicalinc.com and follow us on LinkedIn and YouTube.
The FieldForce™ PFA System is an investigational device and is limited by federal (or United States) law to investigational use.
Media Contact
Holly Windler
619.929.1275
media@fieldmedicalinc.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
JACC: Clinical Electrophysiology Publishes 12-Month Outcomes from Field Medical's First-in-Human Field PULSE Trial: 94.2% Per-Vein PVI Durability with Optimized Waveform
